Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Uterine Neoplasms

NCT01998178: Immune Response and Safety Study of Human Papillomavirus (HPV) Vaccine in HIV-infected Pre-adolescent in Kenya

Active, not recruiting

180

RoW

Quadrivalent HPV Vaccine, Gardasil

Kenyatta National Hospital, University of Washington, Merck

Genital Warts, Cervical Cancer

08/15

12/15

NCT01561586: Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

Recruiting

374

RoW

Weekly cisplatin with RT, Cisplatin, Tri-weekly cisplatin with RT

Korea Cancer Center Hospital, Seoul National University Hospital, Asan Medical Center, Gangnam Severance Hospital

Cervical Cancer

03/20

03/23

NCT01312753: PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer

	ASCO 2014
	May 2014 - May 2014: ASCO 2014

Active, not recruiting

MK-2206

Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Endometrial Cancer

01/16

NCT01835171: Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer

Active, not recruiting

Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiotherapy, External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Internal Radiation Therapy, BRACHYTHERAPY, Internal Radiation, Internal Radiation Brachytherapy, Radiation Brachytherapy, Laboratory Biomarker Analysis, Triapine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, 3-Apct, OCX-191

National Cancer Institute (NCI)

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer, Stage II Vaginal Cancer, Stage IIA1 Cervical Cancer, Stage IIA2 Cervical Cancer, Stage IIB Cervical Cancer, Stage III Vaginal Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Squamous Cell Carcinoma

01/16

DEPICT, NCT01793701: Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer

Active, not recruiting

1/2

Europe

intensity modulated radiotherapy, IMRT, Intracavitary brachytherapy, Cisplatin

Queen Mary University of London, Barts & The London NHS Trust, Barts Cancer Institute

Locally Advanced Cervical Cancer

04/16

04/18

NCT01926821: Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy

Recruiting

200

RoW

Sonifilan, sizofiran inj 20mg, Code : XSISO

Asan Medical Center

Cervical Cancer

12/25

NCT01628757: Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer

Recruiting

N/A

1400

RoW

Ding Ma, Zhejiang University, Shandong University, Sun Yat-sen University, Wuhan University, Hubei Women and Children's Hospital, Wuhan General Hospital of Guangzhou Military Command, Xiangfan Central Hospital, Wuhan Central Hospital, Hubei University for nationalities

Cervical Cancer

12/18

12/23

EC-02, NCT01820884: The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma

Active, not recruiting

N/A

240

RoW

TH, TH/BSO, BPLND

Ding Ma, Shandong University, Huazhong University of Science and Technology, Zhejiang University

Endometrial Neoplasms

12/25

12/26

NCT01393470: Evaluation of Long-term HPV Vaccine Efficacy

Enrolling by invitation

N/A

10000

Europe

Screening for cervical cancer

Tampere University, FinnMedi Oy, GlaxoSmithKline

Uterine Cervical Cancer

12/24

NCT01164735: Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Completed

N/A

169

Laboratory Biomarker Analysis

Gynecologic Oncology Group, National Cancer Institute (NCI)

Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer

01/18

NCT01198171: Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer

Completed

N/A

243

Laboratory Biomarker Analysis, Study of Socioeconomic and Demographic Variables

Gynecologic Oncology Group, National Cancer Institute (NCI)

Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer

02/17

NCT01344837: Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

Completed

N/A

360

Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Cell/Tissue, Immunohistochemistry, IHC, Immunohistochemistry, Medical Chart Review, Chart Review, Microarray Analysis, gene expression profile, Gene Expression Profiling, Microarray Technology, Microarray-Based Analysis, Study of Socioeconomic and Demographic Variables, Western Blotting, Blotting, Western, WESTERN BLOT

Gynecologic Oncology Group, National Cancer Institute (NCI)

Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer

01/18

NCT01199250: Biomarkers in Samples From Patients With Endometrial Cancer

Withdrawn

N/A

3600

Laboratory Biomarker Analysis

Gynecologic Oncology Group, National Cancer Institute (NCI)

Lynch Syndrome, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer

05/19



	Diseases Companies Products Productz Mechanisms of Action Sites